Pharma News

Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, a member of the Roche Group, resolving pending disputes over Pebrilzo® (bPertuzumab), its biosimilar version of Perjeta® (pertuzumab), a biologic medicine used in the treatment of HER2-positive breast cancer.

A common asthma medication improves motor skills and muscle strength in children with congenital myopathies, a group of incurable muscle diseases. In a study, children receiving the drug were able to both walk and stand up more quickly.

Shri Prataprao Jadhav, Union Minister of State (Independent Charge) for Ayush and Minister of State for Health & Family Welfare, today emphasised that traditional systems of medicine, when supported by scientific research, appropriate clinical evidence, quality standards and responsible integration, can make a significant contribution to strengthening preventive healthcare and holistic well-being across the world.

The proposal, notified through Gazette Notification G.S.R. 861(E), dated 28 September 2026, seeks to extend advertising restrictions for medicines listed under Schedule H, Schedule H1 and Schedule X to entities holding licences for the sale and distribution of drugs.

Zydus Lifesciences Limited and Formycon AG have announced that the US Food and Drug Administration (USFDA) has accepted the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda® (pembrolizumab), for review.

A new review in Genes & Diseases highlights FTO, an enzyme involved in RNA modification, as a potentially important biomarker and therapeutic target across gastrointestinal cancers. The article brings together current understanding of FTO in gastric, liver, colorectal and pancreatic cancers, revealing a complex role in which the enzyme can both promote and suppress cancer progression depending on biological context.

A survey of 539 people with Lynch syndrome highlights a gap between evidence supporting aspirin-based cancer prevention and its implementation in clinical practice, despite strong interest in preventive research.

Rubicon Research Limited has received one observation in a Form 483 issued by the United States Food and Drug Administration (US FDA) following an unannounced inspection of its manufacturing facility in Satara, Maharashtra.

Solid tumors are not merely collections of malignant cells but complex ecosystems comprising tumor cells, stromal cells, and the extracellular matrix (ECM). The tumor microenvironment (TME) fosters immunosuppression through tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and cancer-associated fibroblasts (CAFs), while physical barriers such as dense ECM and abnormal vasculature hinder drug penetration